Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates
08:31pm, Tuesday, 05'th Nov 2024
MacroGenics (MGNX) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.52 per share a year ago.
MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript
07:01pm, Tuesday, 05'th Nov 2024
MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Ko
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
04:01pm, Tuesday, 05'th Nov 2024
ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibod
MacroGenics Announces Leadership Transition
07:30am, Wednesday, 30'th Oct 2024
ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
04:30pm, Tuesday, 29'th Oct 2024
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based ther
Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders
05:15pm, Friday, 25'th Oct 2024
WILMINGTON, DE / ACCESSWIRE / October 25, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
07:30am, Tuesday, 22'nd Oct 2024
ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX
10:00am, Wednesday, 25'th Sep 2024
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX).
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX
07:00pm, Tuesday, 24'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities law
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities law
Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX
12:57pm, Tuesday, 24'th Sep 2024
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)
11:25am, Tuesday, 24'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities law
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against MacroGenics, Inc.
11:00am, Tuesday, 24'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGen
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
10:30am, Tuesday, 24'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)--MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm.
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky
10:15am, Tuesday, 24'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities law
